Amylyx Pharmaceuticals Inc
AMLX12.330USD
-0.160-1.28%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
More Details of Amylyx Pharmaceuticals Inc Company
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Amylyx Pharmaceuticals Inc Info
Ticker SymbolAMLX
Company nameAmylyx Pharmaceuticals Inc
IPO dateJan 07, 2022
CEOKlee (Justin)
Number of employees123
Security typeOrdinary Share
Fiscal year-endJan 07
Address43 Thorndike Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141
Phone16176820917
Websitehttps://www.amylyx.com/
Ticker SymbolAMLX
IPO dateJan 07, 2022
CEOKlee (Justin)
Company Executives of Amylyx Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
175.76K
-3.61%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
175.76K
-3.61%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.17%
Perceptive Advisors LLC
8.15%
Adage Capital Management, L.P.
6.21%
TCG Crossover Management, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.48%
Other
64.31%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.17%
Perceptive Advisors LLC
8.15%
Adage Capital Management, L.P.
6.21%
TCG Crossover Management, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.48%
Other
64.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.51%
Hedge Fund
33.27%
Investment Advisor/Hedge Fund
16.31%
Private Equity
9.12%
Individual Investor
7.46%
Venture Capital
3.62%
Research Firm
2.78%
Bank and Trust
0.07%
Pension Fund
0.04%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
396
113.87M
99.16%
+1.57M
2025Q3
421
112.47M
102.70%
+27.99M
2025Q2
403
84.84M
117.02%
+7.84M
2025Q1
405
77.30M
91.06%
-3.38M
2024Q4
410
53.16M
117.27%
+2.39M
2024Q3
404
54.08M
130.01%
-4.93M
2024Q2
400
54.22M
128.23%
-6.16M
2024Q1
379
60.25M
120.54%
-21.45M
2023Q4
360
66.89M
115.11%
-1.53M
2023Q3
329
65.21M
99.39%
+4.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
11.38M
10.67%
+8.33M
+273.33%
Sep 30, 2025
Perceptive Advisors LLC
7.90M
7.41%
+28.02K
+0.36%
Jun 30, 2025
Adage Capital Management, L.P.
8.80M
8.25%
+3.10M
+54.45%
Jun 30, 2025
TCG Crossover Management, LLC
5.94M
5.57%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.85M
4.55%
+2.79M
+135.51%
Jun 30, 2025
The Vanguard Group, Inc.
4.50M
4.22%
+381.52K
+9.27%
Jun 30, 2025
Saturn V Capital Management LP
3.26M
3.06%
+834.13K
+34.38%
Jun 30, 2025
Klee (Justin B)
3.33M
3.12%
-29.98K
-0.89%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.5%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco Dorsey Wright SmallCap Momentum ETF
1.15%
Invesco Dorsey Wright Healthcare Momentum ETF
1.03%
Federated Hermes MDT Small Cap Core ETF
0.51%
iShares U.S. Pharmaceuticals ETF
0.42%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Vanguard US Momentum Factor ETF
0.14%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.5%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.38%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion1.15%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.03%
Federated Hermes MDT Small Cap Core ETF
Proportion0.51%
iShares U.S. Pharmaceuticals ETF
Proportion0.42%
iShares Micro-Cap ETF
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.16%
Vanguard US Momentum Factor ETF
Proportion0.14%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Amylyx Pharmaceuticals Inc?
The top five shareholders of Amylyx Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC holds 11.38M shares, accounting for 10.67% of the total shares.
Perceptive Advisors LLC holds 7.90M shares, accounting for 7.41% of the total shares.
Adage Capital Management, L.P. holds 8.80M shares, accounting for 8.25% of the total shares.
TCG Crossover Management, LLC holds 5.94M shares, accounting for 5.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.85M shares, accounting for 4.55% of the total shares.
Fidelity Management & Research Company LLC holds 11.38M shares, accounting for 10.67% of the total shares.
Perceptive Advisors LLC holds 7.90M shares, accounting for 7.41% of the total shares.
Adage Capital Management, L.P. holds 8.80M shares, accounting for 8.25% of the total shares.
TCG Crossover Management, LLC holds 5.94M shares, accounting for 5.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.85M shares, accounting for 4.55% of the total shares.
What are the top three shareholder types of Amylyx Pharmaceuticals Inc?
The top three shareholder types of Amylyx Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC
Perceptive Advisors LLC
Adage Capital Management, L.P.
Fidelity Management & Research Company LLC
Perceptive Advisors LLC
Adage Capital Management, L.P.
How many institutions hold shares of Amylyx Pharmaceuticals Inc (AMLX)?
As of 2025Q4, 396 institutions hold shares of Amylyx Pharmaceuticals Inc, with a combined market value of approximately 113.87M, accounting for 99.16% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.55%.
What is the biggest source of revenue for Amylyx Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Amylyx Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
